<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03136861</url>
  </required_header>
  <id_info>
    <org_study_id>CAIN457H3301</org_study_id>
    <secondary_id>2017-000401-21</secondary_id>
    <nct_id>NCT03136861</nct_id>
  </id_info>
  <brief_title>SKIPPAIN - Speed of Onset of SecuKinumab-Induced Relief From Pain in Patients With AxIal SpoNdyloarthritis</brief_title>
  <acronym>SKIPPAIN</acronym>
  <official_title>A 24-week, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Secukinumab in Controlling Spinal Pain in Patients With Axial Spondyloarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study was to evaluate the efficacy and safety of secukinumab 150 mg
      compared to placebo in the early management (Baseline to Week 8) of spinal pain, disease
      activity, fatigue, and predictability of disease flares in patients with axial
      spondyloarthritis (axSpA) who had an inadequate response to prior non-steroidal
      anti-inflammatory drugs (NSAIDs). This study also explored the efficacy and safety of
      secukinumab 300 mg compared to secukinumab 150 mg from Week 8 to Week 24 in order to assess
      the potential additional benefits of dose escalation in patients with axSpA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consisted of 2 treatment periods: a double-blind, placebo-controlled period from
      Baseline to Week 8 (Treatment Period 1) and a double-blind secukinumab treatment period from
      Week 8 to Week 24 (Treatment Period 2).

      At Baseline (Treatment Period 1), patients were randomized in a 3:1 ratio to either
      secukinumab 150 mg (Group A) or placebo (Group B). At Week 8 (Treatment Period 2), patients
      were re-randomized and re-assigned respectively to 1 of 5 treatment arms to receive either
      secukinumab 150 mg or secukinumab 300 mg.

      Patients assigned to secukinumab 150 mg (Group A) at Baseline who were responders (i.e.
      spinal pain score &lt; 4) at Week 8 continued on the same dose until Week 24 under 1 treatment
      arm (Arm A1). Patients assigned to secukinumab 150 mg at Baseline who were non-responders at
      Week 8 were re-randomized to 1 of 2 treatment arms: secukinumab 150 mg (Arm A2) or
      secukinumab 300 mg (Arm A3) from Week 8 to Week 24.

      Similarly, patients assigned to placebo (Group B) at Baseline were re-randomized to 1 of 2
      treatment arms: secukinumab 150 mg (Arm B1) or secukinumab 300 mg (Arm B2) from Week 8 until
      Week 24.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 30, 2017</start_date>
  <completion_date type="Actual">February 15, 2019</completion_date>
  <primary_completion_date type="Actual">February 15, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With a Spinal Pain Numerical Rating Scale (NRS) Score Below 4 at Week 8 (Treatment Period 1)</measure>
    <time_frame>Week 8</time_frame>
    <description>The spinal pain numerical rating scale (NRS) is an 11-point scale to assess pain intensity in patients who are able to self-report. It is an 11-point scale from 0-10: 1) &quot;0&quot; = no pain. 2) &quot;10&quot; = the most intense pain imaginable. To calculate the average spinal pain, the patient was asked to answer 2 questions to get 2 pain ratings, the total spinal pain corresponding to the intensity of spinal pain experienced on an average over 24 hours during the previous week and the nocturnal back pain corresponding to the intensity of spinal pain experienced on an average over the night during the previous week.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Bath Ankylosing Spondylitis Disease Activity Index Score Below 4 at Week 8 (Treatment Period 1)</measure>
    <time_frame>Week 8</time_frame>
    <description>The Bath ankylosing spondylitis disease activity index (BASDAI) consists of a 0 through 10 scale, which is used to answer 6 questions pertaining to the 5 major symptoms of ankylosing spondylitis. To give each symptom equal weighting, the mean (average) of the 2 scores relating to morning stiffness (questions 5 and 6) is taken. The mean of questions 5 and 6 is added to the scores from questions 1-4. The resulting 0 to 50 score is divided by 5 to give a final 0 - 10 BASDAI score.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">383</enrollment>
  <condition>Spondyloarthritis</condition>
  <arm_group>
    <arm_group_label>Secukinumab 150 mg (Group A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Period 1: Secukinumab 150 mg (1 x 1.0 mL) s.c. administered at Baseline, Week 1, 2, 3 and 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Group B)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment Period 1: Placebo (1 x 1.0 mL) s.c. administered at Baseline and Week 1, 2, 3 and 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment Period 2: Secukinumab 150 mg (1 x 1.0 mL) plus placebo (1 x 1.0 mL) administered at Week 8, 12, 16 and 20</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment Period 2: Secukinumab 150 mg (1 x 1.0 mL) plus placebo (1 x 1.0 mL) administered at Week 8, 12, 16 and 20</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment Period 2: Secukinumab 300 mg (2 x 1.0 mL) administered at Week 8, 12, 16, and 20</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment Period 2: Secukinumab 150 mg (1 x 1.0 mL) plus placebo (1 x 1.0 mL) administered at Week 8, 12, 16 and 20</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment Period 2: Secukinumab 300 mg (2 x 1.0 mL) administered at Week 8, 12, 16, and 20</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AIN457</intervention_name>
    <description>anti IL-17a monoclonal antibody</description>
    <arm_group_label>Arm A1</arm_group_label>
    <arm_group_label>Arm A2</arm_group_label>
    <arm_group_label>Arm A3</arm_group_label>
    <arm_group_label>Arm B1</arm_group_label>
    <arm_group_label>Arm B2</arm_group_label>
    <arm_group_label>Placebo (Group B)</arm_group_label>
    <arm_group_label>Secukinumab 150 mg (Group A)</arm_group_label>
    <other_name>secukinumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AIN457 Placebo</intervention_name>
    <description>Placebo matching AIN457</description>
    <arm_group_label>Arm A1</arm_group_label>
    <arm_group_label>Arm A2</arm_group_label>
    <arm_group_label>Arm B1</arm_group_label>
    <arm_group_label>Placebo (Group B)</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Diagnosis of axial spondylarthritis (axSpA, either ankylosing spondylitis or non
             radiographic axial spondylarthritis) according to ASAS axSpA classification criteria

          -  patients with back pain for at least 3 months and age of onset less than 45 years

          -  Active axSpA as assessed by total BASDAI score of at least 4 at Baseline.

          -  Spinal pain numeric rating scale score of more than 4 at Baseline.

          -  inadequate response to or failure to respond to at least 2 different NSAIDs at the
             highest recommended dose for at least 4 weeks in total prior to randomization

        Key Exclusion Criteria:

          -  Chest X-ray or MRI with evidence of ongoing infectious or malignant process

          -  Patients previously treated with any biological immunomodulating agents, except those
             targeting tumor necrosis factor alpha.

          -  Patients who have been exposed to more than one anti-tumor necrosis factor alpha
             agent.

          -  Active ongoing inflammatory diseases other than axial spondyloarthritis

          -  Other ongoing mechanical diseases affecting the spine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brussel</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Burgas</city>
        <zip>8000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1413</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1505</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1750</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zagreb</city>
        <state>HRV</state>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rijeka</city>
        <zip>51000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brno</city>
        <zip>63800</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plzen-Bory</city>
        <zip>30599</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha 5</city>
        <zip>150 06</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Parnu</city>
        <zip>80010</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tallinn</city>
        <zip>10138</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tartu</city>
        <zip>50406</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kuopio</city>
        <zip>70100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kuovola</city>
        <zip>45100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alexandroupolis</city>
        <state>Evros</state>
        <zip>681 00</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Thessaloniki</city>
        <state>GR</state>
        <zip>564 29</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <zip>145 61</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54636</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dublin 4</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dublin</city>
        <zip>D03 VX82</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Verona</city>
        <state>VR</state>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liepaja</city>
        <zip>LV 3401</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riga</city>
        <zip>LV 1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riga</city>
        <zip>LV 2164</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaunas</city>
        <state>LTU</state>
        <zip>LT 50161</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaunas</city>
        <state>LT</state>
        <zip>LT-50128</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowian</state>
        <zip>02 495</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85 168</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sopot</city>
        <zip>81 756</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>00-874</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>04 305</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>53-224</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Irkutsk</city>
        <zip>664046</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Izhevsk</city>
        <zip>426009</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kazan</city>
        <zip>420097</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>115093</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Voronezh</city>
        <zip>394036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <zip>03203</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Elda</city>
        <state>Alicante</state>
        <zip>03600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucia</state>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucia</state>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Galdakao</city>
        <state>Bizkaia</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Torrelavega</city>
        <state>Cantabria</state>
        <zip>39300</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plasencia</city>
        <state>Extremadura</state>
        <zip>10600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lugo</city>
        <state>Galicia</state>
        <zip>27003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Orense</city>
        <state>Galicia</state>
        <zip>32005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mallorca</city>
        <state>Islas Baleares</state>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Torrejon de Ardoz</city>
        <state>Madrid</state>
        <zip>28850</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <zip>38010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stockholm</city>
        <state>SE</state>
        <zip>113 65</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Danderyd</city>
        <zip>182 88</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Halmstad</city>
        <zip>SE 302 66</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Harnosand</city>
        <zip>SE 871 31</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St Gallen</city>
        <zip>CH 9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zuerich</city>
        <zip>CH 8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stoke on Trent</city>
        <state>Staffordshire</state>
        <zip>ST6 7AG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liverpool</city>
        <zip>L9 7AL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warrington</city>
        <zip>WA5 1QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wolverhampton</city>
        <zip>WV10 0QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Croatia</country>
    <country>Czechia</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>Greece</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 28, 2017</study_first_submitted>
  <study_first_submitted_qc>April 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 2, 2017</study_first_posted>
  <results_first_submitted>February 5, 2020</results_first_submitted>
  <results_first_submitted_qc>February 5, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 19, 2020</results_first_posted>
  <last_update_submitted>May 1, 2020</last_update_submitted>
  <last_update_submitted_qc>May 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>axial spondyloarthritis</keyword>
  <keyword>ankylosing spondylitis</keyword>
  <keyword>non-radiographic axial spondyloarthritis</keyword>
  <keyword>inflammatory back pain</keyword>
  <keyword>spinal pain</keyword>
  <keyword>secukinumab</keyword>
  <keyword>AIN457</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is commited to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.</ipd_description>
    <ipd_time_frame>Upon request</ipd_time_frame>
    <ipd_url>http://www.clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 29, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT03136861/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 7, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT03136861/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at 66 centers in 17 countries worldwide: Spain(14), Czech Republic(3), Finland(2), Lithuania(2), Estonia(3), Latvia(3), Switzerland(1), Russia(4), Sweden(4), United Kingdom(5), Belgium(2), Ireland(2), Poland(7), Croatia(3), Bulgaria(5), Greece(5), Italy(1).</recruitment_details>
      <pre_assignment_details>At Baseline, patients were randomized to either secukinumab 150 mg or placebo (Group A or B). At Week 8, patients were re-randomized or re-assigned respectively to 1 of 5 treatment arms to receive either secukinumab 150 mg or secukinumab 300 mg (Arm A1 to B2).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Secukinumab 150 mg (Group A)</title>
          <description>Treatment Period 1: Secukinumab 150 mg (1 x 1.0 mL) s.c. administered at Baseline, Week 1, 2, 3 and 4</description>
        </group>
        <group group_id="P2">
          <title>Placebo (Group B)</title>
          <description>Treatment Period 1: Placebo (1 x 1.0 mL) s.c. administered at Baseline and Week 1, 2, 3 and 4</description>
        </group>
        <group group_id="P3">
          <title>Arm A1</title>
          <description>Treatment Period 2: Secukinumab 150 mg (1 x 1.0 mL) plus placebo (1 x 1.0 mL) administered at Week 8, 12, 16 and 20</description>
        </group>
        <group group_id="P4">
          <title>Arm A2</title>
          <description>Treatment Period 2: Secukinumab 150 mg (1 x 1.0 mL) plus placebo (1 x 1.0 mL) administered at Week 8, 12, 16 and 20</description>
        </group>
        <group group_id="P5">
          <title>Arm A3</title>
          <description>Treatment Period 2: Secukinumab 300 mg (2 x 1.0 mL) administered at Week 8, 12, 16, and 20</description>
        </group>
        <group group_id="P6">
          <title>Arm B1</title>
          <description>Treatment Period 2: Secukinumab 150 mg (1 x 1.0 mL) plus placebo (1 x 1.0 mL) administered at Week 8, 12, 16 and 20</description>
        </group>
        <group group_id="P7">
          <title>Arm B2</title>
          <description>Treatment Period 2: Secukinumab 300 mg (2 x 1.0 mL) administered at Week 8, 12, 16, and 20</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period 1 (TP1)(Baseline-Wk 8)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="285"/>
                <participants group_id="P2" count="95"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="278"/>
                <participants group_id="P2" count="89"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject/Guardian Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal of Informed Consent</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period 2 (TP2) (Wk 8-Wk 24)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="90"/>
                <participants group_id="P4" count="94"/>
                <participants group_id="P5" count="94"/>
                <participants group_id="P6" count="45"/>
                <participants group_id="P7" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="88"/>
                <participants group_id="P4" count="93"/>
                <participants group_id="P5" count="92"/>
                <participants group_id="P6" count="45"/>
                <participants group_id="P7" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal of Informed Consent</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>At Baseline Treatment Period 1, 380 patients were randomized to either secukinumab 150 mg or placebo (Group A or B). All the patients who completed Treatment Period 1 (367) were re-randomized or re-assigned respectively to 1 of 5 treatment arms to receive either secukinumab 150 mg or secukinumab 300 mg (Arm A1 to B2) in Treatment Period 2.</population>
      <group_list>
        <group group_id="B1">
          <title>Secukinumab 150 mg (Group A)</title>
          <description>Treatment Period 1: Secukinumab 150 mg (1 x 1.0 mL) s.c. administered at Baseline, Week 1, 2, 3 and 4</description>
        </group>
        <group group_id="B2">
          <title>Placebo (Group B)</title>
          <description>Treatment Period 1: Placebo (1 x 1.0 mL) s.c. administered at Baseline and Week 1, 2, 3 and 4</description>
        </group>
        <group group_id="B3">
          <title>Arm A1</title>
          <description>Treatment Period 2: Secukinumab 150 mg (1 x 1.0 mL) plus placebo (1 x 1.0 mL) administered at Week 8, 12, 16 and 20</description>
        </group>
        <group group_id="B4">
          <title>Arm A2</title>
          <description>Treatment Period 2: Secukinumab 150 mg (1 x 1.0 mL) plus placebo (1 x 1.0 mL) administered at Week 8, 12, 16 and 20</description>
        </group>
        <group group_id="B5">
          <title>Arm A3</title>
          <description>Treatment Period 2: Secukinumab 300 mg (2 x 1.0 mL) administered at Week 8, 12, 16, and 20</description>
        </group>
        <group group_id="B6">
          <title>Arm B1</title>
          <description>Treatment Period 2: Secukinumab 150 mg (1 x 1.0 mL) plus placebo (1 x 1.0 mL) administered at Week 8, 12, 16 and 20</description>
        </group>
        <group group_id="B7">
          <title>Arm B2</title>
          <description>Treatment Period 2: Secukinumab 300 mg (2 x 1.0 mL) administered at Week 8, 12, 16, and 20</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="285"/>
            <count group_id="B2" value="95"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="0"/>
            <count group_id="B5" value="0"/>
            <count group_id="B6" value="0"/>
            <count group_id="B7" value="0"/>
            <count group_id="B8" value="380"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Age continuous at Baseline Treatment Period 1</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.3" spread="11.88"/>
                    <measurement group_id="B2" value="40.9" spread="12.20"/>
                    <measurement group_id="B8" value="42.0" spread="11.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Gender at Baseline Treatment Period 1</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B8" value="145"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="179"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B8" value="235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Race at Baseline Treatment Period 1</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="267"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B8" value="360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B8" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B8" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Spinal Pain Numerical Rating Scale (NRS) Score Below 4 at Week 8 (Treatment Period 1)</title>
        <description>The spinal pain numerical rating scale (NRS) is an 11-point scale to assess pain intensity in patients who are able to self-report. It is an 11-point scale from 0-10: 1) &quot;0&quot; = no pain. 2) &quot;10&quot; = the most intense pain imaginable. To calculate the average spinal pain, the patient was asked to answer 2 questions to get 2 pain ratings, the total spinal pain corresponding to the intensity of spinal pain experienced on an average over 24 hours during the previous week and the nocturnal back pain corresponding to the intensity of spinal pain experienced on an average over the night during the previous week.</description>
        <time_frame>Week 8</time_frame>
        <population>Full Analysis Set (FAS) in Treatment Period 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab 150 mg (Group A)</title>
            <description>Treatment Period 1: Secukinumab 150 mg (1 x 1.0 mL) s.c. administered at Baseline, Week 1, 2, 3 and 4</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Group B)</title>
            <description>Treatment Period 1: Placebo (1 x 1.0 mL) s.c. administered at Baseline and Week 1, 2, 3 and 4</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Spinal Pain Numerical Rating Scale (NRS) Score Below 4 at Week 8 (Treatment Period 1)</title>
          <description>The spinal pain numerical rating scale (NRS) is an 11-point scale to assess pain intensity in patients who are able to self-report. It is an 11-point scale from 0-10: 1) &quot;0&quot; = no pain. 2) &quot;10&quot; = the most intense pain imaginable. To calculate the average spinal pain, the patient was asked to answer 2 questions to get 2 pain ratings, the total spinal pain corresponding to the intensity of spinal pain experienced on an average over 24 hours during the previous week and the nocturnal back pain corresponding to the intensity of spinal pain experienced on an average over the night during the previous week.</description>
          <population>Full Analysis Set (FAS) in Treatment Period 1.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="279"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Average Spinal Pain Score</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="188"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Spinal Pain Score</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="187"/>
                    <measurement group_id="O2" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nocturnal Spinal Pain Score</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="202"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Average Spinal Pain Score &lt;4 at Week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0264</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression model: logit (proportion) = treatment + stratification factor of prior exposure to TNF inhibitors (i.e. TNF-nave or TNF-IR).</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.08</ci_lower_limit>
            <ci_upper_limit>3.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Total Spinal Pain Score &lt;4 at Week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0043</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression model: logit (proportion) = treatment + stratification factor of prior exposure to TNF inhibitors (i.e. TNF-nave or TNF-IR)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.31</ci_lower_limit>
            <ci_upper_limit>4.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Nocturnal Spinal Pain Score</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0720</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression model: logit (proportion) = treatment + stratification factor of prior exposure to TNF inhibitors (i.e. TNF-nave or TNF-IR)</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>3.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Bath Ankylosing Spondylitis Disease Activity Index Score Below 4 at Week 8 (Treatment Period 1)</title>
        <description>The Bath ankylosing spondylitis disease activity index (BASDAI) consists of a 0 through 10 scale, which is used to answer 6 questions pertaining to the 5 major symptoms of ankylosing spondylitis. To give each symptom equal weighting, the mean (average) of the 2 scores relating to morning stiffness (questions 5 and 6) is taken. The mean of questions 5 and 6 is added to the scores from questions 1-4. The resulting 0 to 50 score is divided by 5 to give a final 0 - 10 BASDAI score.</description>
        <time_frame>Week 8</time_frame>
        <population>Full Analysis Set (FAS) in Treatment Period 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab 150 mg (Group A)</title>
            <description>Treatment Period 1: Secukinumab 150 mg (1 x 1.0 mL) s.c. administered at Baseline, Week 1, 2, 3 and 4</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Group B)</title>
            <description>Treatment Period 1: Placebo (1 x 1.0 mL) s.c. administered at Baseline and Week 1, 2, 3 and 4</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Bath Ankylosing Spondylitis Disease Activity Index Score Below 4 at Week 8 (Treatment Period 1)</title>
          <description>The Bath ankylosing spondylitis disease activity index (BASDAI) consists of a 0 through 10 scale, which is used to answer 6 questions pertaining to the 5 major symptoms of ankylosing spondylitis. To give each symptom equal weighting, the mean (average) of the 2 scores relating to morning stiffness (questions 5 and 6) is taken. The mean of questions 5 and 6 is added to the scores from questions 1-4. The resulting 0 to 50 score is divided by 5 to give a final 0 - 10 BASDAI score.</description>
          <population>Full Analysis Set (FAS) in Treatment Period 1.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="280"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes (n=95,22)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No (n=185,70)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="185"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>BASDAI Score &lt;4 at Week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0466</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression model: logit (proportion) = treatment + stratification factor of prior exposure to TNF inhibitors (i.e. TNF-nave or TNF-IR).</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.01</ci_lower_limit>
            <ci_upper_limit>3.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment emergent adverse events were collected from first dose of study treatment until end of study treatment plus 12 weeks, up to a maximum duration of 32 weeks.</time_frame>
      <desc>Any sign or symptom that occurs after written informed consent provided. Treatment emergent adverse events were reported until end of study treatment plus 12 weeks post treatment.
Treatment emergent adverse events occurring during Treatment Period 1 are recorded in Group A and B arms.
Treatment emergent adverse events occurring during Treatment Period 2 are recorded in Arm A1 to Arm B2.</desc>
      <group_list>
        <group group_id="E1">
          <title>Secukinumab 150 mg (Group A)</title>
          <description>Treatment Period 1: Secukinumab 150 mg (1 x 1.0 mL) s.c. administered at Baseline, Week 1, 2, 3 and 4</description>
        </group>
        <group group_id="E2">
          <title>Placebo (Group B)</title>
          <description>Treatment Period 1: Placebo (1 x 1.0 mL) s.c. administered at Baseline and Week 1, 2, 3 and 4</description>
        </group>
        <group group_id="E3">
          <title>Arm A1</title>
          <description>Treatment Period 2: Secukinumab 150 mg (1 x 1.0 mL) plus placebo (1 x 1.0 mL) administered at Week 8, 12, 16 and 20</description>
        </group>
        <group group_id="E4">
          <title>Arm A2</title>
          <description>Treatment Period 2: Secukinumab 150 mg (1 x 1.0 mL) plus placebo (1 x 1.0 mL) administered at Week 8, 12, 16 and 20</description>
        </group>
        <group group_id="E5">
          <title>Arm A3</title>
          <description>Treatment Period 2: Secukinumab 300 mg (2 x 1.0 mL) administered at Week 8, 12, 16, and 20</description>
        </group>
        <group group_id="E6">
          <title>Arm B1</title>
          <description>Treatment Period 2: Secukinumab 150 mg (1 x 1.0 mL) plus placebo (1 x 1.0 mL) administered at Week 8, 12, 16 and 20</description>
        </group>
        <group group_id="E7">
          <title>Arm B2</title>
          <description>Treatment Period 2: Secukinumab 300 mg (2 x 1.0 mL) administered at Week 8, 12, 16, and 20</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (21.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Renal mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (21.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="13" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Iritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Frequent bowel movements</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertransaminasaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Viral pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Lactose intolerance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ankylosing spondylitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Muscle contracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vulvovaginal pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>Novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

